Total Reports
7
Low report volume
Horse /
Breed profile · FDA CVM July 2026 extract
Lippizzaner adverse-event record
Adverse-event filings for Lippizzaner (Horse) in the FDA Center for Veterinary Medicine openFDA extract. Browse horse breeds, reactions, and outcomes below.
- #470 of 510
- by report volume (all breeds)
- 7
- FDA CVM reports on file
- 42.9%
- death-coded share of reports
- 3
- Death by euthanasia - top reaction
How the 7 reports break down
By recorded gender -- every report on file for Lippizzaner, no filtering.
Annual report volume
Data updated September 2026
The verdict
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Lippizzaner ranks #460 of 510 by total reports (7). Death-coded-share rank requires at least 50 reports. National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).
- 93,675
- Retriever - Labrador reports (#1)
- 99.0%
- Atlantic Salmon (Salmo salar) death share (#1)
- #460
- This breed, reports of 510
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Lippizzaner has 7 reports now versus 7 in that prior snapshot: 0 the same number of (0.0%).
- Report change
- +0
- Death-coded reports
- +0
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Lippizzaner changesDeaths Reported
3
of 7 reports
Death-coded share of reports
42.9%
42.9% death-coded
Avg Age at Report
19.7 yr
484.2 kg avg weight
Death-Coded Outcome Share
Lippizzaner death-coded reports 42.9%
Cross-breed median
42.9% of 7 lippizzaner reports involved a death outcome.
How to read this number
Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 484.2 kg (1067.7 lbs)
Top Reported Reactions
Death by euthanasia 3
INEFFECTIVE, SEDATION 2
Laminitis 1
Decreased appetite 1
Ataxia 1
Most Referenced Drugs
Pergolide Mesylate 3
Praziquantel; Moxidectin 1
Ketamine Hydrochloride 1
Xylazine 1
Oxybendazole 1
Outcome Breakdown
Outcome Unknown
3 (42.9%)
Euthanized
3 (42.9%)
Recovered/Normal
1 (14.3%)
Gender Distribution
Male 4 (57.1%)
Female 2 (28.6%)
Unknown 1 (14.3%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2013 | 1 | |
| 2014 | 1 | |
| 2015 | 1 | |
| 2017 | 2 | |
| 2021 | 1 | |
| 2023 | 1 | |
Lippizzaner: high death-coded share in the FDA CVM extract
Signature read: 7 reports place Lippizzaner in the lower third of breed filing volume (#470 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Lippizzaner sits at #470 of 510 by report volume among all breeds and #47 of 55 among horse breeds, with 7 reports and 3 (42.9%) death-coded. Mean age at report: 19.7 years, average weight 484.2 kg (1067.7 lbs).
Top reported signs: Death by euthanasia (3), INEFFECTIVE, SEDATION (2), Laminitis (1). Most-referenced drug: Pergolide Mesylate (3 reports), followed by Praziquantel; Moxidectin (1) and Ketamine Hydrochloride (1).
Outcome coding on 7 status-recorded reports is dominated by Outcome Unknown (42.9%). Annual submissions ranged 1-2,023 across 6 years on file.
Horse Breeds With a Similar Report Volume
Showing 6 of 54 horse breeds in our dataset, ranked by closest report volume.
Nationwide breeds with similar profiles
Sparse-volume peer sets for Lippizzaner drawn from openFDA outside the Horse family so the neighborhoods are not species containment (the similar-volume list above stays within species).
Similar average weight
Nearest other-species breeds by reported average weight (484.2 kg here).
What to do with this horse
- Compare Lippizzaner's report volume and death-coded share against similar-volume breeds nationwide. See similar breeds
- Read how death-coded share differs from a mortality rate before drawing conclusions. Breed-specific risks guide
- Browse every horse breed we track for comparison. All horse breeds
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Frequently Asked Questions
How many FDA adverse event reports involve Lippizzaner? ▼
There are 7 adverse event reports involving Lippizzaner in the FDA database, of which 3 were death-coded (42.9% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Lippizzaner ranks #470 of 510 by report volume among all breeds PlainBreed indexes (#47 of 55 among horse breeds).
Where does Lippizzaner sit among other breeds in PlainBreed's corpus? ▼
According to FDA CVM report volume, Lippizzaner is #470 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Horse, it is #47 of 55. It has fewer than 50 reports, so it is outside the death-rate ranking cohort (≥50 reports). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Lippizzaner? ▼
The most commonly reported adverse reactions for Lippizzaner are Death by euthanasia (3 reports), INEFFECTIVE, SEDATION (2 reports), Laminitis (1 reports), Decreased appetite (1 reports), Ataxia (1 reports).
What drugs are most frequently associated with Lippizzaner adverse events? ▼
The drugs most frequently referenced in Lippizzaner adverse event reports are Pergolide Mesylate (3 reports), Praziquantel; Moxidectin (1 reports), Ketamine Hydrochloride (1 reports), Xylazine (1 reports), Oxybendazole (1 reports).
What is the average age of Lippizzaner in adverse event reports? ▼
The average age of Lippizzaner at the time of adverse event reports is 19.7 years, with an average weight of 484.2 kg (1067.7 lbs).
Compare a breed's report volume against how common the breed is before drawing conclusions. See our methodology for how the death-coded share and rankings are computed, or read breed-specific reporting patterns and FDA CVM reporting.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
openFDA Animal & Veterinary Adverse Events (FDA CVM) for Lippizzaner (Horse), extract as of July 2026 extract. 7 reports · 3 death-coded (42.9% of reports, not a mortality rate) · #470 of 510 by volume.
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →